TheGLP-1receptoragonistexenatide ameliorates neuroinflammation, locomotor activity, andanxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4
Key pointsGLP-1drugs can transform the health of people with obesity, quiet "food noise," and may level the weight-loss playing field. Research on the drugs' mental health effects is mixed. Experts worry widespread use could fuel sizeism and eating disorders. Psychologists are helpingGLP-1patients develop healthy behaviors and manage body image, identity, and relationshipchanges.
Purpose Glucagon-like peptide-1receptoragonists(GLP-1RAs) are increasingly used for managing metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Beyond their metabolic benefits,GLP-1RAs exhibit neuroprotective and psychotropic effects, potentially benefiting mental health conditions like depression andanxiety. This systematic review aims to synthesize existing ...
The risk of depression,anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1receptoragonisttherapy What is the pipeline for future medications for obesity?
This systematic review examines the current literature on glucagon-like peptide-1receptoragonists(GLP-1RAs)-associated psychiatric manifestations, including depression, suicidality, eating disorders, substance use disorders (SUD) and schizophrenia spectrum disorders. A comprehensive literature search was conducted to identify studies evaluating the association betweenGLP-1RAs and ...
In short, emotionalglp-1effects are real, typically manageable, and best addressed with intentional monitoring, behavioral strategies, and timely clinical communication. If you trackchangesglp-1closely and use a step-by-step plan, you can reduce risks and maximize benefits during treatment.
